SFE Investment Counsel’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-10,055
Closed -$425K – 125
2021
Q4
$425K Buy
10,055
+627
+7% +$27.9K 0.11% 99
2021
Q3
$429K Buy
9,428
+63
+0.7% +$2.89K 0.12% 98
2021
Q2
$458K Buy
9,365
+399
+4% +$19.1K 0.13% 95
2021
Q1
$451K Sell
8,966
-1,869
-17% -$103K 0.13% 92
2020
Q4
$555K Buy
10,835
+2,044
+23% +$97.3K 0.18% 90
2020
Q3
$362K Buy
8,791
+66
+0.8% +$2.72K 0.14% 92
2020
Q2
$365K Sell
8,725
-829
-9% -$32.7K 0.16% 85
2020
Q1
$303K Sell
9,554
-296
-3% -$11.3K 0.17% 92
2019
Q4
$416K Sell
9,850
-280
-3% -$10.4K 0.17% 89
2019
Q3
$320K Buy
10,130
+520
+5% +$18.3K 0.14% 99
2019
Q2
$347K Buy
9,610
+1,826
+23% +$63K 0.15% 97
2019
Q1
$282K Buy
+7,784
New +$260K 0.13% 99

Other funds holding SBIO

SFE Investment Counsel's SBIO Position: Q1 2022 in Review

SFE Investment Counsel sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q1 2022, closing a stake of 10,055 shares — an estimated $425K sold.

SFE Investment Counsel first reported a position in SBIO in Q1 2019 and held it in 12 quarters. The position peaked at $555K in Q4 2020. 56 funds tracked by Wall St. Rank hold SBIO as of Q1 2022.

  • SFE Investment Counsel reported no remaining ALPS Medical Breakthroughs ETF position as of Q1 2022 after selling out during the quarter.
  • SFE Investment Counsel sold 10,055 ALPS Medical Breakthroughs ETF shares in Q1 2022, an estimated $425K.
  • SFE Investment Counsel first reported a position in ALPS Medical Breakthroughs ETF in Q1 2019 and held it in 12 quarters.
  • SFE Investment Counsel's ALPS Medical Breakthroughs ETF position peaked at $555K in Q4 2020.
  • 56 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q1 2022.

Based on SFE Investment Counsel's 13F filing for Q1 2022, filed 6 May 2022.